Compare GSHD & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | GRDN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Retail-Drug Stores and Proprietary Stores |
| Sector | Finance | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2018 | 2024 |
| Metric | GSHD | GRDN |
|---|---|---|
| Price | $75.16 | $28.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $94.70 | $32.00 |
| AVG Volume (30 Days) | 270.9K | ★ 353.0K |
| Earning Date | 10-22-2025 | 11-10-2025 |
| Dividend Yield | ★ 7.83% | N/A |
| EPS Growth | ★ 68.12 | N/A |
| EPS | ★ 1.14 | 0.28 |
| Revenue | $353,231,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | $16.48 | $16.33 |
| Revenue Next Year | $20.04 | $2.10 |
| P/E Ratio | ★ $66.40 | $103.31 |
| Revenue Growth | ★ 25.01 | 18.68 |
| 52 Week Low | $64.41 | $17.78 |
| 52 Week High | $127.99 | $37.43 |
| Indicator | GSHD | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 53.04 |
| Support Level | $69.80 | $27.60 |
| Resistance Level | $72.82 | $30.00 |
| Average True Range (ATR) | 2.13 | 1.61 |
| MACD | 0.71 | -0.13 |
| Stochastic Oscillator | 87.74 | 14.08 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.